Sun Pharma to raise Rs 10,000 crore via debt offering for Organon acquisition

Sun Pharmaceutical Industries Limited is preparing to raise Rs 10,000 crore through a debt securities offering as part of its financing strategy for the Organon acquisition, according to market sources. The Mumbai-based pharmaceutical giant plans to issue bonds across multiple maturity profiles to optimize its capital structure and manage refinancing needs.

The proposed bond issuance is expected to include securities with maturities of two, three and four years, providing the company with flexibility in managing its debt obligations. This multi-tenor approach allows Sun Pharma to balance near-term and medium-term financing requirements while potentially optimizing interest cost management.

The offering represents a key component of Sun Pharma's financial strategy as it integrates Organon into its operations. The debt raise comes as the company seeks to efficiently manage the capital requirements associated with the acquisition while maintaining its market position as India's largest pharmaceutical company by market capitalisation.

The timing and final terms of the bond issuance remain subject to market conditions and regulatory approvals. Such debt offerings are commonly used by large pharmaceutical companies to refinance major acquisitions and strengthen their balance sheets.